The Ever-expanding Landscape of Antibody-Drug Conjugates (ADCs) in Solid Tumors: A Systematic Review

The Ever-expanding Landscape of Antibody-Drug Conjugates (ADCs) in Solid Tumors: A Systematic Review

The advent of targeted therapies signaled novel avenues for more optimal oncological outcomes. Antibody-drug conjugates (ADCs) have risen as a cornerstone of the ever-expanding targeted therapy era. The purpose of this systematic review is to delineate the rapidly evolving clinical landscape of ADCs...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in oncology/hematology Vol. 192; p. 104189
Main Authors: Filis, Panagiotis, Zerdes, Ioannis, Soumala, Theodora, Matikas, Alexios, Foukakis, Theodoros
Format: Journal Article
Language:English
Published: Elsevier B.V 01-12-2023
Subjects:
ADCs
Antibody-drug conjugate
Medicin och hälsovetenskap
phase II
phase III
solid tumors
targeted therapy
targeted therapy
phase II
ADCs
solid tumors
phase III
Antibody-drug conjugate
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The advent of targeted therapies signaled novel avenues for more optimal oncological outcomes. Antibody-drug conjugates (ADCs) have risen as a cornerstone of the ever-expanding targeted therapy era. The purpose of this systematic review is to delineate the rapidly evolving clinical landscape of ADCs for solid tumors. A literature search was performed in Medline, Embase and Cochrane databases for phase II and III clinical trials. Outcomes of interest were the objective response rate, overall survival, progression-free survival and adverse events. A total of 92 clinical trials (76 phase II and 16 phase III) evaluated the efficacy and safety of ADCs for a plethora of solid tumors. Out of the 30 investigated ADCs, 8 have received approval by regulatory organizations for solid tumors. Currently, 52 phase III clinical trials for ADCs are ongoing. ADCs have shown promising results for several solid tumors and various cancer settings. [Display omitted] •The introduction and continuous refinement of ADCs are transforming clinical practice in oncology•Currently 8 ADCs have received regulatory approval for use in solid tumors•92 phase II and III trials have evaluated the use of several ADCs in solid tumors•The results from over 50 ongoing phase III clinical trials are eagerly awaited
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ObjectType-Undefined-4
ISSN:1040-8428
1879-0461
1879-0461
DOI:10.1016/j.critrevonc.2023.104189